Skip to contents

Francisco M. Marty, MD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Infectious Diseases
75 Francis Street
Boston, MA 02115


Edit Profile


Education:
Jose Maria Vargas School of Medicine, Universidad Central de Venezuela, 1993, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Bachta KER, Ozer EA, Pandit A, Marty FM, Mekalanos JJ, Hauser AR. Draft Genome Sequence of Pseudomonas aeruginosa Strain BWH047, a Sequence Type 235 Multidrug-Resistant Clinical Isolate Expressing High Levels of Colistin Resistance. Microbiol Resour Announc. 2019 Jul 18; 8(29).

2. Cheng MP, Marty FM. Reply to Aronson et al. Clin Infect Dis. 2019 Jul 11.

3. Karantanos T, Kim HT, Tijaro-Ovalle NM, Li L, Cutler C, Antin JH, Ballen K, Marty FM, Tan CS, Ritz J, Politikos I, Boussiotis V. Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol. 2019 Jun 27; 207:18-23.

4. Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation. Clin Infect Dis. 2019 Jun 08.

5. Tasigiorgos S, Kollar B, Turk M, Perry B, Alhefzi M, Kiwanuka H, Nizzi MC, Marty FM, Chandraker A, Tullius SG, Riella LV, Pomahac B. Five-Year Follow-up after Face Transplantation. N Engl J Med. 2019 06 27; 380(26):2579-2581.

6. Nucci M, Shoham S, Abdala E, Hamerschlak N, Rico JC, Forghieri F, Nouér SA, Cappellano P, Solza C, Gonzaga Y, Nadali G, Nucci F, Colombo AL, Albuquerque AM, Queiroz-Telles Filho F, Lima CBL, Arrais-Rodrigues C, Rocha V, Marty FM. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis? Mycoses. 2019 May; 62(5):413-417.

7. Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clin Infect Dis. 2019 Apr 08; 68(8):1255-1264.

8. Cheng MP, Kusztos AE, Bold TD, Ho VT, Glotzbecker BE, Hsieh C, Baker MA, Baden LR, Hammond SP, Marty FM. Risk of Latent Tuberculosis Reactivation after Hematopoietic-Cell Transplantation. Clin Infect Dis. 2019 Jan 28.

9. Cheng MP, Marty FM, Costa DB, Awad MM. Authors' Response. J Thorac Oncol. 2018 11; 13(11):e237.

10. Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA, Nichols WG, Boeckh MJ. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.